Article
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial.
The Lancet. Haematology - 1 Mar 2021
Barbui Tiziano, Vannucchi Alessandro Maria, De Stefano Valerio, Masciulli Arianna, Carobbio Alessandra, Ferrari Alberto, Ghirardi Arianna, Rossi Elena, Ciceri Fabio, Bonifacio Massimiliano, Iurlo Alessandra, Palandri Francesca, Benevolo Giulia, Pane Fabrizio, Ricco Alessandra, Carli Giuseppe, Caramella Marianna, Rapezzi Davide, Musolino Caterina, Siragusa Sergio, Rumi Elisa, Patriarca Andrea, Cascavilla Nicola, Mora Barbara, Cacciola Emma, Mannarelli Carmela, Loscocco Giuseppe Gaetano, Guglielmelli Paola, Betti Silvia, Lunghi Francesca, Scaffidi Luigi, Bucelli Cristina, Vianelli Nicola, Bellini Marta, Finazzi Maria Chiara, Tognoni Gianni, Rambaldi Alessandro
Abstract excerpt
BACKGROUND: There is no evidence that phlebotomy alone is sufficient to steadily maintain haematocrit on target level in low-risk patients with polycythaemia vera. This study aimed to compare the efficacy and safety of ropeginterferon alfa-2b on top of the standard phlebotomy regimen with phlebotomy alone. METHODS: In 2017, we launched the Low-PV study, a multicentre, open-label, two-arm, parallel-group,...
Topics
Join the communities discussing this publication.